StockData
Editas Medicine, Inc. logo

Editas Medicine, Inc. (EDIT) stock

EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/309% above fair value
$1.77−0.05 (-3.01%)

Close on Nov 18, 2026Market cap $271.84MP/E –Yield –

Editas Medicine free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Editas Medicine's free cash flow for the twelve months ending Jun 30, 2026 was -$120.55M. For fiscal 2025 it was -$165.85M. The highest annual figure on record is -$6.87M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$165.85M–
FY2024Dec 31, 2024-$219.11M–
FY2023Dec 31, 2023-$136.90M–
FY2022Dec 31, 2022-$181.47M–
FY2021Dec 31, 2021-$171.78M–
FY2020Dec 31, 2020-$187.01M–
FY2019Dec 31, 2019-$46.84M–
FY2018Dec 31, 2018-$50.46M–
FY2017Dec 31, 2017-$11.48M–
FY2016Dec 31, 2016-$53.74M–
FY2015Dec 31, 2015-$6.87M–
FY2014Dec 31, 2014-$9.87M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.67M–
Q1 FY2026Mar 31, 2026-$23.15M–
Q4 FY2025Dec 31, 2025-$36.45M–
Q3 FY2025Sep 30, 2025-$31.28M–
Q2 FY2025Jun 30, 2025-$50.21M–
Q1 FY2025Mar 31, 2025-$47.91M–
Q4 FY2024Dec 31, 2024-$51.30M–
Q3 FY2024Sep 30, 2024-$55.51M–
Q2 FY2024Jun 30, 2024-$60.56M–
Q1 FY2024Mar 31, 2024-$51.74M–
Q4 FY2023Dec 31, 2023-$23.55M–
Q3 FY2023Sep 30, 2023-$35.70M–
Q2 FY2023Jun 30, 2023-$40.04M–
Q1 FY2023Mar 31, 2023-$37.61M–
Q4 FY2022Dec 31, 2022-$42.90M–
Q3 FY2022Sep 30, 2022-$48.62M–
Q2 FY2022Jun 30, 2022-$38.48M–
Q1 FY2022Mar 31, 2022-$51.48M–
Q4 FY2021Dec 31, 2021-$37.43M–
Q3 FY2021Sep 30, 2021-$43.13M–
Q2 FY2021Jun 30, 2021-$41.66M–
Q1 FY2021Mar 31, 2021-$49.56M–
Q4 FY2020Dec 31, 2020-$41.48M-205.4%
Q3 FY2020Sep 30, 2020-$56.59M–
Q2 FY2020Jun 30, 2020-$32.70M–
Q1 FY2020Mar 31, 2020-$56.24M–
Q4 FY2019Dec 31, 2019$39.33M–
Q3 FY2019Sep 30, 2019-$29.13M–
Q2 FY2019Jun 30, 2019-$27.32M–
Q1 FY2019Mar 31, 2019-$29.72M–
Q4 FY2018Dec 31, 2018-$88.00K–
Q3 FY2018Sep 30, 2018-$8.78M–
Q2 FY2018Jun 30, 2018-$18.12M–
Q1 FY2018Mar 31, 2018-$23.47M-133.9%
Q4 FY2017Dec 31, 2017-$25.36M–
Q3 FY2017Sep 30, 2017-$28.73M–
Q2 FY2017Jun 30, 2017-$26.52M–
Q1 FY2017Mar 31, 2017$69.14M–
Q4 FY2016Dec 31, 2016-$14.35M–
Q3 FY2016Sep 30, 2016-$17.75M–

More Editas Medicine figures

See a number that looks wrong?